Naveen Pemmaraju: Navitoclax BCLxL Inhibition in patients with myelofibrosis
Naveen Pemmaraju, Professor at the Department of Leukemia at MD Anderson Cancer Center, shared a post on X, about a paper by him and colleagues, published in Blood Neoplasia:
“New online Paper alert now avails from our MPN group longer-term results and Disease Modification with focus addition of Navitoclax BCLxL inhibition in patients with Myelofibrosis.”
Authors: Naveen Pemmaraju, Tim Somervaille, Francesca Palandri, Jalaja Potluri, Jacqueline Garcia, et al.
Naveen Pemmaraju is a Professor and Director of the BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of the MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.
His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN, and AML.
More posts featuring Naveen Pemmaraju.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023